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Background: Human rhinovirus (HRV) is the most common
respiratory viral infection following hematopoietic cell
transplantation (HCT); the day 100 cumulative incidence is
22%. HRV can progress to lower respiratory tract (LRT)
infection. The clinical signiﬁcance of HRV RNA in LRT secre-
tions is unclear.We analyzed the outcome and risk factors for
mortality in HCT recipients with HRV RNA detection in the
LRT, comparing survival of patients with LRT infection due to
HRV and other respiratory viruses.
Methods: A retrospective cohort of 87 HCT recipients trans-
planted between 6/1993e4/2012 at FHCRC had HRV RNA
detected in LRT by bronchoalveolar lavage (BAL) or biopsy
using culture (N¼13) and/or real time RT-PCR (N¼80); all
patients had LRT symptoms and/or pulmonary inﬁltrates.
Factors associatedwith overallmortalitywere analyzed using
Cox proportional hazards models. Comparison cohorts with
parainﬂuenza virus (PIV, N¼55), RSV (N¼111), or inﬂuenza A
(FLU, N¼41) LRT infection were included in the analyses.
Samples from a separate control cohort of 21 asymptomatic
HCT patientswithout radiographic abnormalities undergoing
research BAL between day 35e50 were also studied.
Results: Median age of the 87 patients was 48.5 years (range
1e71); median time to HRV LRT detection after HCT was 81
days (range0e3596). Viral/fungal/bacterial copathogenswere
present in 48%of patients. Probability of 180-day survival after
HRV detection was 59%. Multivariable analysis showed that
oxygen use at diagnosis (HR 2.6, P¼ .04), steroid use 1mg/kg
prior to diagnosis (HR 5.5, P¼ .002), and bonemarrowas stem
cell source (HR 2.3, P ¼ .05) were associated with poor
outcome. The presence of copathogens did not signiﬁcantly
affect mortality (HR 1.1, P¼ .71) (Figure 1). Survival at day 180
inpatientswithHRVLRT infection and LRT infection causedby
other respiratoryviruseswas similar (Figure1); after adjusting
for stem cell source and baseline steroid and oxygen use, no
statistically signiﬁcant difference in mortality between HRV
and any of the other viruses was found (adjusted HR versus
HRV without copathogens: HRV with copathogens, HR 0.96;
PIV, HR 1.05; RSV, HR 0.93; FLU, HR 1.47). HRVwas detected in
only one asymptomatic control patient (5%).
Conclusions: HCT recipients who underwent BAL or biopsy
for lung diseasewith HRV RNAdetection had a highmortality
even in the absence of copathogens. Outcome was not
statistically signiﬁcantly different from patients with RSV,
inﬂuenza or PIV LRT disease. These results suggest that HRV is
a pathogen that is associated with severe pulmonary disease,
and is associated with mortality rates comparable to well-
recognized viral pathogens. Additional studies are ongoing to
deﬁne the role of viral load and HRV genotypes on outcome.
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Introduction: The impaired B and T cell immunity of HCT
recipients increases their susceptibility to infectious diseases
like herpes zoster (HZ). However, the licensed live-attenu-
ated HZ vaccine is not appropriate for highly immunocom-
promised individuals. Recombinant subunit vaccines are an
alternative to live-attenuated vaccines. VZV glycoprotein E
(gE) is an attractive candidate antigen. We report on the
safety and immunogenicity of two formulations of a VZV
subunit vaccine candidate administered on a 2- or 3-dose
schedule to autologous HCT recipients.
Methods: This was a Phase I/II, randomized, placebo-
controlled, multicenter study. Adults with multiple
myeloma, non-Hodgkin B or T cell lymphoma, Hodgkin
lymphoma, or acute myeloid leukemia who had undergone
autologous HCT 50e70 days earlier were randomized 1:1:1:1
to receive 3 doses (at months 0, 1, and 3) of 50 mg gE
combined with the adjuvant AS01B (50 mg MPL/QS21) or
AS01E (25 mg MPL/QS21), 1 dose of saline followed by 2 doses
of gE/AS01B, or 3 doses of saline. Serum anti-gE antibody
concentrations were measured by ELISA and frequencies
of gE-speciﬁc CD4+ T cells expressing 2 activation
markers by intracellular cytokine staining up to month 15.
Solicited local and systemic adverse events (AEs) were
recorded up to 7 days after each immunization (graded 1e3).
Unsolicited AEs were reported from the ﬁrst immunization
up to 30 days after the ﬁnal immunization. Serious AEs
were reported throughout the study. (Clinicaltrials.gov,
NCT00920218).
Results: 120 subjects were vaccinated. gE-speciﬁc antibody
concentrations and activated CD4+ T cell frequencies were
higher with all gE/AS01 regimens than with saline at month
4 and persisted up to month 15 (all P < .0001). For gE/AS01B,
3 doses were more immunogenic than 2, but 3 doses of gE/
AS01B were not signiﬁcantly more immunogenic than 3
doses of gE/AS01E. The most common solicited AEs were
pain, fatigue, andmyalgia. Overall, grade 3 AEs were reported
in 10.3%e36.7% of vaccine and6.7% of saline recipients. One
non-fatal SAE was considered possibly related to vaccination
in the gE/AS01B 2-dose group. Eleven subjects died, of which
seven died from malignancy recurrence. Four cases of HZ
were conﬁrmed during the study, two each in the gE/AS01E3-
dose and saline groups.
Abstracts / Biol Blood Marrow Transplant 19 (2013) S167eS177 S169Conclusions: Both gE/AS01B and gE/AS01E formulations and
both schedules were immunogenic and well tolerated in
autologous HCT recipients.Table 1
Etanercept arm Placebo arm p
Day 28 Response 62.5% (95%CI:
35.4-84.8)
66.7% (95%CI: 41.0-86.7) .80
Day 56 Response 56.3% (95%CI:
29.9-80.3)
50.0% (95%CI: 26.0-74.0) .72
6 month OS 50.0% (95%CI:
24.5-71.0)
33.3% (95%CI: 13.6-54.5)
Median survival 171 days (95%CI:
11-362)
64 days (95%CI: 26-209)
Log-rank (OS) .51108
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IPS is a frequently fatal form of non-infectious pneumonia
occurring early after allogeneic SCT. We conducted a phase III
trial to investigate if a soluble TNF binding protein, etanercept
(Enbrel Amgen), when givenwith corticosteroids, improved
management of IPS. The study was supported by the NHLBI
andNCI,with etanercept supplied byAmgen. Eligible patients
were 18 yrs, within 180 days post allo-SCT, with diffuse
pulmonary inﬁltrates, and absence of active infection, sepsis
syndrome, or cardiogenic shock. A negative BALwas required
at study entry. Patients were randomized to receive eta-
nercept (0.4 mg/kg/dose 2x/week x 4 weeks) or placebo, in
addition to corticosteroids (2.0mg/kg/day,with taperallowed
after 7 days). Response was deﬁned as survival with discon-
tinuation of supplemental oxygen for>72 hours by day 28 of
study. The trial was initially designed to enroll 120 patients,
with sufﬁcient power to identify a 25% response difference
(30% to 55%) between study arms. Due to suboptimal accrual,
inclusion criteria were modiﬁed and expected enrollment
decreased to 60 patients, 30 per arm. The trial did not meet
accrual goals and was stopped after enrolling 34 patients.
Results: Between 2007 and 2011, 34 patients (median age
46.6y, range 22-70 y) were randomized to receive etanercept
(n¼16) or placebo (n¼18). Study arms were balanced for
patient demographics, except for a higher incidence of AML in
the placebo arm (50% vs 6%, P ¼ .02). 50% of etanercept and
55% of placebo treated patients received all intended study
doses, whereas 38% of etanercept and 6% of placebo treated
patients received 25% of intended dosing (primarily inves-
tigator discretion). Response at day 28 and day 56, and overall
survival were comparable between groups (Table 1). There
were no differences in time to discontinuation of supple-
mental oxygen, incidence of grades 3-5 adverse events,
infections, cumulative incidence of relapse, or grades 2-4or 3-
4 acute GVHD. Patients receiving 40% FiO2 at study entry
had response rates of 91% (placebo) and 73% (etanercept)respectively. By comparison, responses in patients receiving
>40% FiO2 at entry were 17% (1 of 6) on the placebo arm and
50% (2 of 4) on the etanercept arm.
Conclusion: No improvement in response or survival was
noted when etanercept was added to corticosteroids for the
treatment of IPS, though the small sample size signiﬁcantly
limits the statistical power of this study. Compared to
historical reports, the response to corticosteroids alone was
higher than anticipated supporting the importance of
studying controls when evaluating a new therapy.TRANSPLANT DATA MANAGEMENT ORAL109
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Background: To ensure the highest degree of accuracy of
CIBMTR (Center for International Blood and Marrow Trans-
plant Research) data, the University of Maryland Blood and
Marrow Transplant team established a culture of continuous
quality improvement. In early 2012, Minas and Ruehle re-
ported the signiﬁcance of auditing 10 commonly used data
collection points. Since that time, their program set out to
identify additional data points of signiﬁcance.
Methods: The Blood and Marrow Transplant Program
Manager and Data Managers continued to evaluate the
quality of their data by selecting 19 additional data points for
audit to assess the signiﬁcance of adding these additional
data points to the 10 commonly used ones. The CIBMTR
forms of four subjects per month (40%) were randomly
selected for audit from August 2011 to August 2012, for
a total of 48 charts.
Results: Our results demonstrated that adding the extra data
points covers 90% of the data reported while the commonly
used data points cover only 50% of the data reported; thereby
demonstrating a more comprehensive review of the infor-
mation reported. Implementing the regular internal audit
using the 10 commonly used data points demonstrated
better percentage (range 89% to 100%) of data accuracy from
that previously reported before implementing the regular
internal audit. When the 19 additional data points were
reviewed as a whole, there was a 96% accuracy rate.
Corrective action was taken by reviewing all CIBMTR forms
with less than 100% accuracy rate and correcting the data in
the electronic database. Education is given on the individual
level and for the group as trends become prevalent.
Conclusion: Implementing internal audits on a regular basis
using the commonly used data points and the additional 19
data points have improved the accuracy of the data from
what has been previously reported. By maintaining
